JOINN (06127) surged more than 5%. As of press time, the stock was up 5.06%, trading at HKD 25.74, with a turnover of HKD 116 million. The company recently released its annual results forecast, anticipating a net profit attributable to shareholders of approximately RMB 233 million to RMB 349 million for 2025, representing a year-on-year increase of about 214.0% to 371.0%. Regarding the reasons for the profit growth, JOINN stated in its announcement that during the reporting period, the market price increase of biological assets, coupled with their natural growth appreciation, drove a positive fair value change, making a positive contribution to the company's performance. Specifically, the change in the fair value of biological assets contributed approximately RMB 452 million to RMB 500 million to the net profit. In January of this year, Yin Hongfei, a senior investment consultant at Yuekai Securities, noted in a media interview that developing a new drug from the laboratory to clinical trials consumes an average of 60 lab monkeys, with the usage for large-molecule drugs doubling. Furthermore, he mentioned that according to recent market reports and calculations by Founder Securities, the price per crab-eating macaque, a key species, surged to RMB 120,000-130,000 within a month, with some scarce supplies quoted as high as RMB 150,000, marking an increase of over 30% compared to two months ago.